Instrumento Inactivo

Otros idiomas MEDIGENE NA Swiss Exchange

Acciones

OXMDGG

DE0005020903

Precio de cierre Swiss Exchange Otros sitios de cotización
- ^EUR	-

21/05	Medigene y BioNTech amplían su colaboración en inmunoterapia contra el cáncer	MT
21/05	El acuerdo global de investigación y colaboración de Medigene AG con BioNTech SE se extenderá más allá del plazo inicial anunciado	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Medigene, BioNTech Extend Cancer Immunotherapy Partnership	21/05
Medigene AG's Global Research & Collaboration Agreement with BioNTech SE to Extend Beyond Initial Announced Term	21/05
Medigene AG Presents Preclinical Data on Optimal Affinity TCRs Targeting the Neoantigen Mutant KRAS	15/05
Medigene Ag Maintains Earnings Guidance for 2024	14/05
Medigene Boosts Share Capital Via Rights Offering, Private Placement	08/05
Medigene AG Expands Patent Portfolio with European Patent Grant for its NY-ESO-1 - Targeted T Cell Receptor	02/05
Medigene Presents Superior TCR-T Cell Functionality by Inclusion of A Costimulatory Switch Protein	02/05
Medigene AG Presents Streamlined 6-Day, High Stemness Tcr-T Therapy Production Process	25/04
Rights Issue: 1 new share @ 1.2 EUR for 5 existing shares	24/04	FA
Medigene AG Presents Favorable Safety Profile of TCR-T Cells with Costimulatory Switch Protein at AACR Annual Meeting 2024	08/04
Medigene Gets European Patent for T-Cell Receptor Technology	04/04
Medigene AG Secures European Patent for Its iM-TCR Technology	04/04
Medigene AG Reports Earnings Results for the Full Year Ended December 31, 2023	29/03
Transcript : Medigene AG, 2023 Earnings Call, Mar 28, 2024	28/03
Medigene Ag Provides Earnings Guidance for 2024	28/03
Medigene AG Expands Patent Portfolio in Japan for iM-TCR Technology to Directly Control TCR-T Safety and Efficacy	04/03
Medigene AG Announces Indication Selection for the Clinical Development of Its Lead 3Rd Generation Tcr-T Therapy Program in Solid Tumors	12/02
Medigene AG Maintains Financial Guidance for the Fiscal Year 2023	21/11
Medigene Presents New Data for MDG 2011, the First TCR in a Novel Kras Library	04/11
Medigene AG Presents First Pre-Clinical Data of Optimal Affinity TCR Targeting mKRAS G12V Combined with a PD1-41BB Costimulatory Switch Protein Showing	23/10/23

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas MEDIGENE NA Swiss Exchange

Acciones

OXMDGG

DE0005020903

Otros idiomas

Filtros